Back to Newsroom

Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis

NORWOOD, MA — (Marketwired) — 07/13/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that patient dosing has commenced in a Phase 2 clinical study of its investigational drug Resunabfor the treatment of skin-predominant dermatomyositis.

Click here to read more